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Abstract: 
 
Background: Several in vitro diagnostic (IVD) test kits for hepatitis B surface antigen (HBsAg) are 
commercially available. The question is whether they are performing well for both screening and diagnosis or 
not? Thus, this study aimed to evaluate the performance of six commercially available HBsAg detection kits in 
Togo.  
Methods: This study was conducted at the National Reference Center for HIV/STI testing in Lomé (CNR-
VIH/IST), Togo. Reference sera used for the assessment were collected from blood donors and patients with 
history of hepatitis B viral (HBV) infection between 2008 and 2014, and includes 200 non-reactive HBsAg and 
150 reactive HBsAg sera that were confirmed with a reference method which consisted of the combination of an 
ELISA, a RDT, and a molecular test. Four ELISA kits (EKOlab ELISA-HBsAg; HEPALISA ULTRA; HEPALISA; 
Murex AgHBs Version 3) and two RDTs kits (ACON AgHBs and OnSite HBsAg Rapid Test-Cassette) were then 
evaluated using these serum samples. The EPI-INFO software version 7.2 was used to determine the 95% 
confidence interval and performed statistical analysis.  
Results: Reference serum samples were collected from the population with 65.0% under 40 years of age and 
61.2% males. The sensitivity of the 4 ELISA tests compared to the reference method was 100%. Apart from 
the HEPALISA test with a specificity of 100.0%, the specificity of the other three ELISA tests (Murex HBsAg 
version 3, HEPALISA ULTRA and EKOlab ELISA-HBsAg) were 98.4%, 97.3% and 91.8% respectively. For the 
RDTs, the sensitivity of ACON HBsAg and OnSite HBsAg Rapid Test-Cassette was 70.0% and 95.6% 
respectively while the specificity was 100.0% for both.  
Conclusion: The ELISA tests evaluated were more sensitive than the RDTs, and HEPALISA test was the most 
efficient. Of the two RDTs, the OnSite HBsAg Rapid Test-Cassette was more sensitive. Our findings highlight the 
need for onsite verification of in vitro diagnostic kits for qualitative detection of hepatitis B surface antigen 
before their routine use in Togo.  
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Contexte: Plusieurs kits de test de diagnostic in vitro (DIV) pour l'antigène de surface de l'hépatite B (HBsAg) 
sont disponibles dans le commerce. La question est de savoir s'ils fonctionnent bien pour le dépistage et le 
diagnostic ou non? Ainsi, cette étude visait à évaluer les performances de six kits de détection de HBsAg 
disponibles dans le commerce au Togo.                          
Méthodes: Cette étude a été réalisée au Centre national de référence pour le dépistage du VIH/IST à Lomé 
(CNR-VIH/IST), Togo. Les sérums de référence utilisés pour l'évaluation ont été collectés auprès de donneurs 
de sang et de patients ayant des antécédents d'infection virale par le virus de l'hépatite B (VHB) entre 2008 et 
2014, et comprennent 200 sérums HBsAg non réactifs et 150 sérums réactifs HBsAg qui ont été confirmés avec 
une méthode de référence consistant en la combinaison d'un ELISA, d'un TDR et d'un test moléculaire. Quatre 
kits ELISA (EKOlab ELISA-HBsAg; HEPALISA ULTRA; HEPALISA; Murex AgHBs Version 3) et deux kits TDR 
(ACON AgHBs et OnSite HBsAg Rapid Test-Cassette) ont ensuite été évalués à l'aide de ces échantillons de 
sérum. Le logiciel EPI-INFO version 7.2 a été utilisé pour déterminer l'intervalle de confiance à 95% et a 
effectué une analyse statistique.                                                  
Résultats: Des échantillons de sérum de référence ont été prélevés dans la population dont 65,0% ont moins 
de 40 ans et 61,2% d'hommes. La sensibilité des 4 tests ELISA par rapport à la méthode de référence était de 
100%. Hormis le test HEPALISA avec une spécificité de 100,0%, la spécificité des trois autres tests ELISA 
(Murex HBsAg version 3, HEPALISA ULTRA et EKOlab ELISA-HBsAg) était respectivement de 98,4%, 97,3% et 
91,8%. Pour les TDR, la sensibilité de la cassette de test rapide ACON HBsAg et OnSite HBsAg était 
respectivement de 70,0% et 95,6% tandis que la spécificité était de 100,0% pour les deux.                
Conclusion: Les tests ELISA évalués étaient plus sensibles que les TDR et le test HEPALISA était le plus 
efficace. Sur les deux TDR, la cassette de test rapide OnSite HBsAg était plus sensible. Nos résultats soulignent 
la nécessité d'une vérification sur site des kits de diagnostic in vitro pour la détection qualitative de l'antigène 
de surface de l'hépatite B avant leur utilisation en routine au Togo. 




 Hepatitis B virus (HBV) is a DNA virus 
that causes acute and chronic hepatitis in 
humans. It is estimated that two billion 
people worldwide have contracted HBV and 
240 million are chronic carriers of the virus. 
Every year, about 600,000 people die from 
late-onset HBV infection. HBV infection is 
hyper endemic in sub-Saharan Africa and 
Asia and is thought to be the major 
etiological factor in more than 75% of 
patients with chronic liver disease (1-3). It 
remains the leading cause of liver cirrhosis 
and hepatocellular carcinoma (HCC), two 
major causes of mortality worldwide (4). 
 Most of HBV-infected persons remain 
asymptomatic for long periods but are at risk 
of progressive liver disease and can transmit 
the virus to other susceptible individuals. 
Early identification of infection is thus 
important. The primary marker for screening 
and laboratory diagnosis of HBV infection is 
hepatitis B surface antigen (HBsAg), a 
component of the virus envelope that is also 
found in the blood in large amount as non-
infectious subviral particles. This small 
envelope protein is the first viral marker to 
appear after HBV infection, and can be found 
in the blood before the onset of symptoms or 
abnormalities of blood chemistry. Thus, 
HBsAg test has been at the forefront of blood 
screening for HBV infection (5). 
 Immunoassays for detection of HBsAg 
required the use of highly sensitive and 
specific test reagents. In recent years, there 
has been an increase in the frequency of HBV 
which   HBsAg  antigenic  determinants  have  
 
undergone one or more mutations as a result 
of natural or therapeutic pressure induced by 
therapy or vaccination. These mutations 
modify the structure of the epitope with 
possible consequence of non-recognition of 
the mutated antigens by the antibodies used 
in the HBsAg screening reagents (6,7). Ther- 
efore, the objective of this study is to conduct 
an on-site assessment of the performance of 
6 diagnostic test kits manufactured for HBsAg 
detection in humans.  
Materials and Method: 
 
Study setting 
 The study was conducted at the 
National Reference Center for HIV/STI (CNR-
VIH/IST) located at the Sylvanus Olympio 
University Teaching Hospital (CHU SO), 
Lomé, Togo. One of the activities of this 
laboratory required by the Ministry of Health, 
is the evaluation of all HIV, viral hepatitis and 
STIs diagnostic test kits that can be used in 
the country for diagnosis or screening of 
donor’s blood for transfusion. 
 
Subjects and sample collection 
 Five ml of venous blood was obtained 
in EDTA Vacutainer tubes from each donor 
received at the National Blood Transfusion 
Center and in dry Vacutainer tubes from 
patients with history of HBV infection at the 
CHU SO, Lomé, Togo. The blood sample was 
centrifugated at 3000rpm for 5 minutes, then 
1-2ml serum or plasma obtained after 
centrifugation were stored at -20°C in CNR-
VIH/IST.  




Detection of HBsAg by the IVD test kits and 
reference method 
 On these samples, we first prepared 
our reference panel by using a combination of 
an ELISA test kit (Monolisa HBsAg ULTRA, 
BIO-RAD, France) and RDT kit (Determine 
HBsAg, Abbott, Japan) in line with the WHO 
recommendation (8), and confirmed negative 
samples by a molecular test. Thus, on all 
plasma negative with the two tests, HBV DNA 
viral load was carried out on 500µL of plasma 
with the m2000rt Abbott Real Time HBV DNA 
assay (Abbott, USA), according to the manu- 
facturer’s protocol. We considered as true 
positive (TP) any sample that gave a positive 
result on both tests, and true negative (TN) 
as any sample that tested negative in both 
tests and in the molecular test. 
 The HBsAg was then detected from 
the serum using four different enzyme linked 
immunosorbent assay (ELISA) kits and two 
rapid diagnostic test kits The four ELISA tests 
were EKOlab ELISA-HBs Ag (EKOlab, Russia), 
HEPALISA ULTRA (Laboratoire J. Mitra & Co., 
India), HEPALISA (Laboratoire J. Mitra & Co., 
India), and Murex AgHBs Version 3 (Murex 
Biotech Limited., UK), and the two RDTs were 
ACON AgHBs (ACON Laboratories, NC., USA) 
and OnSite HBsAg Rapid Test-Cassette (CTK 
Biotech, Inc., USA) (Table 1). The tests were 
performed in accordance with each manu- 
facturer’s protocol.  
 
Statistical analysis 
 The EPI-INFO software version 7.2 
was used to determine the 95% confidence 
interval (CI) of each value. The performance 
of each test was obtained by determining the 
sensitivity (Se), specificity (Sp), positive 
predictive value (PPV) and negative 
predictive value (NPV). The sensitivity was 
defined as the ability of the test kit to truly 
identify persons infected [Se=TP/(TP+FN) x 
100], specificity as the ability of the test kit 
to truly identify persons not infected 
[Sp=TN/(TN+FP) x 100], PPV as the ability of 
the assay to correctly identify actual infected 
persons among all who tested positive with 
the particular kit used [PPV=TN/(TN+FP) x 
100], while NPV was defined as the ability of 
the assay to correctly identify actual non-
infected persons among those who tested 
negative with the kit used [NPV=TN/(TN+FN) 
x 100].  
 
  






 The panel of reference samples used 
to evaluate these HBsAg test kits was 
gradually established from 2008 to 2014. It 
consisted of 350 samples, including 200 non-
reactive HBsAg samples and 150 reactive 
HBsAg samples. All these samples were 
collected from the population with 65% under 
40 years of age and 61.2% males. The 
sample size assessed ranged from 100 to 274 
depending on the number of tests available 
per kit (Table 2). 
 The sensitivity of the 4 ELISA test kits 
was 100% as there were no false negative 
reactions with any of them. Apart from the 
HEPALISA test which gave no false positive 
results, the others 3 ELISA tests gave false 
positive results with 15 of 182 negative sera 
for the EKOlab ELISA-HBsAg test, 3 of 183 
negative sera for HEPALISA ULTRA and 3 of 
150 negative sera for Murex AgHBs Version 3 
testing positive, giving specificity of 100.0%, 
98.4%, 97.3% and 91.8% respectively. The 
PPV of these ELISA test kits ranged from 
85.5% to 100.0% and the NPV was 100.0% 
for all of them. 
 In comparison, the sensitivity of the 
RDT kits were 70.0% for ACON HBsAg and 
95.6% for OnSite HBsAg Rapid Test-Cassette, 
while both kits gave a specificity value of 
100.0%. The PPV for the 2 kits was 100.0% 
while the NPV were 76.9% and 95.7% 
respectively for ACON HBsAg and OnSite 




 We conducted a field evaluation to 
assess the performance of 6 IVD test kits for 
hepatitis B virus infection screening. These 
tests detect the surface antigen (HBsAg) of 
the hepatitis B virus. The screening for viral 
hepatitis B is a dire need in our environment. 
While a lot have been done to provide quality 
and reliable screening for HIV infection with a 
well-defined algorithm, this is not yet the 
case for viral hepatitis, including hepatitis B. 
 Data from an unpublished study 
showed that about 10 RDTs without WHO 
prequalification are available in Togo and 
used at different levels of healthcare 
services. One of CNR-VIH/IST missions is to 
ensure the quality and performance of test 
kits used for the diagnosis of HIV, hepatitis B 
and C, and syphilis in Togo. This involves 
evaluating the on-site performance of the 
proposed test kits.  
 
  




 The major challenge is to choose the 
right reference test i. e. the gold standard. 
For our purpose, we first defined our 
reference panel based on combination of an 
ELISA test (Monolisa HBsAg ULTRA, BIO-
RAD, France) and RDT (Determine HBsAg, 
Abbott, Japan) in line with WHO recom- 
mendation (8). In addition, we confirmed 
negative samples by molecular tools. Our 
assessment showed all the four ELISA tests 
to be more sensitive (100.0% sensitivity) 
than the two RDTs, and amongst these four, 
HEPALISA kit along with the two RDTs had 
specificity of 100.0%. These findings indicate 
clearly that one of these ELISA test kits can 
be chosen for HBV screening of blood donors 
in Togo. In terms of performance, our 
findings demonstrated the efficiency of the 
ELISA kits in the order HEPALISA>Murex 
AgHBs Version 3>HEPALISA ULTRA>EKOlab 
ELISA-HBs-Ag, and of the RDTs in the order 
OnSite HBsAg Rapid Test-Cassette>ACON 
AgHBs. 
 Although the ELISA tests appeared to 
be superior, they are expensive and time 
consuming to perform. Despite the significant 
burden of disease due to HBV and HIV co-
infections, and the advances and oppor- 
tunities for treatment, the majority of people 
infected with HBV remain undiagnosed and 
unaware of their infection (9). It is estimated 
that less than 5% of people with chronic 
hepatitis B or C viral infection know their 
status (8,9), and in low-and-middle-income 
settings, this is even lower (<1%). This is 
also particularly poor in key populations such 
as people who inject drugs, prisoners, sex 
workers and men who have sex with men, for 
whom access to care and treatment are 
already challenging (10).  
 Our goal is to increase accessibility to 
hepatitis B testing by implementing HBV 
screening in community, primary care and 
district hospital in Togo. If we want to 
increase access to HBV testing, we need 
accurate, practical and affordable assays that 
may be used at service delivery of hepatitis B 
testing or near to point of care (11). 
Although, many brands of RDTs claim to 
possess these abilities, the ACON AgHBs we 
evaluated here showed lack of sensitivity. 
The consequence will be misidentification of 
HBV infection cases. Although the RDT assays 
had low sensitivity, their high specificity 
indicates that they may be useful for 
screening in regions endemic for HBV such as 
Togo (12). Moreover, OnSite HBsAg Rapid 
Test-Cassette can be used on whole blood 
and be stored at laboratory temperature like 
the ACON AgHBs. Some studies conducted in 
lower-middle-income countries such as 
Cameroon (13) and Nigeria (14), identified 
another type of RDT kit to be more sensitive.  
 For all the six test kits, the PPV was 
greater than 85.0% and 100.0% for the 2 
RDTs, which somewhat further support their 
use in endemic region where people who test 
negative could complete their screening by 
either an EIA or PCR technique when these 
tools are available, to increase accuracy of 
screening. In Togo, previous studies have 
reported HBV prevalence ranging approxi- 
mately between 9% to 19% (15-17). Thus, in 
Togo HBV RDT could be used in key 
populations at care services and in high risk 
population such as those in the age range 
20-39 years old in Lomé (17) and on 
students (18) during screening campaigns. 
However, for blood transfusion, only ELISA 
assays or RDT kits with high performance as 
regard sensitivity or specificity should be 
used for HBsAg screening for blood 
transfusion (19-22). 
 One limitation to this study is the fact 
that these evaluations were not done at the 
same period, and sample sizes for the 
different kits were also not the same, 
situations that could have effect on 
comparisons of performance between the test 




 From this study, the ELISA test kits 
showed better performance than the RDTs. A 
good assay for an infectious agent such as 
HBV from a diagnostic point of view is one 
with a high positive predictive value and high 
specificity (23). The most effective test kit in 
this study is HEPALISA and the most effective 
RDT is OnSite HBsAg Rapid Test-Cassette. 
Our findings highlight the need of onsite 
assessment and verification of HBV diagnosis 
test kits before their routine use in the 
country. 
 We recommend that assays including 
rapid test kits used for HBsAg screening 
should be validated by the CNR/VIH before 
use for routine screening in Togo. It is crucial 
to expand hepatitis testing services, 
especially in community-based settings, 
where there are challenges with cost, 
transport and venipuncture requirements. 
The RDTs with best accuracy in this study can 
be used as an alternative screening tool for 
HBV infection at the community or primary 
healthcare level, more so that they are 
simple to perform by minimally trained 
community workers. 
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